vs
BuzzFeed, Inc.（BZFD）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
BuzzFeed, Inc.的季度营收约是REGENXBIO Inc.的1.9倍（$56.5M vs $30.3M），BuzzFeed, Inc.净利率更高（-47.4% vs -221.3%，领先173.9%），REGENXBIO Inc.同比增速更快（43.0% vs 0.6%），BuzzFeed, Inc.自由现金流更多（$-12.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 23.6%）
BuzzFeed Inc.是总部位于美国纽约的互联网数字媒体公司，主营新闻与娱乐内容业务，由乔纳·佩雷蒂与约翰·约翰逊三世于2006年创立，最初以追踪 viral 热门传播内容为核心方向，原赫芬顿邮报联合创始人肯尼思·勒勒作为联合创始投资人，现担任公司执行董事长。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BZFD vs RGNX — 直观对比
营收规模更大
BZFD
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出42.4%
0.6%
净利率更高
BZFD
高出173.9%
-221.3%
自由现金流更多
BZFD
多$40.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
23.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.5M | $30.3M |
| 净利润 | $-26.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -43.7% | -190.0% |
| 净利率 | -47.4% | -221.3% |
| 营收同比 | 0.6% | 43.0% |
| 净利润同比 | -186.4% | -31.2% |
| 每股收益（稀释后） | $-0.72 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BZFDRGNX
| Q4 25 | $56.5M | $30.3M | ||
| Q3 25 | $46.3M | $29.7M | ||
| Q2 25 | $46.4M | $21.4M | ||
| Q1 25 | $36.0M | $89.0M | ||
| Q4 24 | $56.2M | $21.2M | ||
| Q3 24 | $55.6M | $24.2M | ||
| Q2 24 | $41.1M | $22.3M | ||
| Q1 24 | $37.0M | $15.6M |
净利润BZFDRGNX
| Q4 25 | $-26.8M | $-67.1M | ||
| Q3 25 | $-7.4M | $-61.9M | ||
| Q2 25 | $-10.8M | $-70.9M | ||
| Q1 25 | $-12.7M | $6.1M | ||
| Q4 24 | $31.0M | $-51.2M | ||
| Q3 24 | $2.1M | $-59.6M | ||
| Q2 24 | $-7.5M | $-53.0M | ||
| Q1 24 | $-35.7M | $-63.3M |
毛利率BZFDRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BZFDRGNX
| Q4 25 | -43.7% | -190.0% | ||
| Q3 25 | -12.9% | -176.3% | ||
| Q2 25 | -7.5% | -296.3% | ||
| Q1 25 | -38.1% | 13.6% | ||
| Q4 24 | 7.0% | -242.1% | ||
| Q3 24 | 2.8% | -256.6% | ||
| Q2 24 | -13.6% | -251.3% | ||
| Q1 24 | -63.4% | -408.8% |
净利率BZFDRGNX
| Q4 25 | -47.4% | -221.3% | ||
| Q3 25 | -16.1% | -208.3% | ||
| Q2 25 | -23.3% | -331.8% | ||
| Q1 25 | -35.2% | 6.8% | ||
| Q4 24 | 55.2% | -241.3% | ||
| Q3 24 | 3.8% | -246.3% | ||
| Q2 24 | -18.2% | -237.7% | ||
| Q1 24 | -96.5% | -405.4% |
每股收益（稀释后）BZFDRGNX
| Q4 25 | $-0.72 | $-1.30 | ||
| Q3 25 | $-0.20 | $-1.20 | ||
| Q2 25 | $-0.28 | $-1.38 | ||
| Q1 25 | $-0.33 | $0.12 | ||
| Q4 24 | $0.86 | $-0.99 | ||
| Q3 24 | $0.05 | $-1.17 | ||
| Q2 24 | $-0.20 | $-1.05 | ||
| Q1 24 | $-0.98 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $49.4M | $102.7M |
| 总资产 | $188.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BZFDRGNX
| Q4 25 | $8.5M | $230.1M | ||
| Q3 25 | $34.3M | $274.2M | ||
| Q2 25 | $29.7M | $323.3M | ||
| Q1 25 | $34.3M | $267.9M | ||
| Q4 24 | $22.4M | $234.7M | ||
| Q3 24 | $53.7M | $255.5M | ||
| Q2 24 | $45.5M | $290.4M | ||
| Q1 24 | $44.5M | $338.7M |
股东权益BZFDRGNX
| Q4 25 | $49.4M | $102.7M | ||
| Q3 25 | $75.9M | $161.5M | ||
| Q2 25 | $81.1M | $213.7M | ||
| Q1 25 | $93.8M | $274.2M | ||
| Q4 24 | $104.8M | $259.7M | ||
| Q3 24 | $71.7M | $301.4M | ||
| Q2 24 | $67.2M | $348.3M | ||
| Q1 24 | $73.7M | $390.7M |
总资产BZFDRGNX
| Q4 25 | $188.1M | $453.0M | ||
| Q3 25 | $211.2M | $525.2M | ||
| Q2 25 | $210.4M | $581.0M | ||
| Q1 25 | $203.2M | $490.9M | ||
| Q4 24 | $221.4M | $466.0M | ||
| Q3 24 | $276.5M | $519.1M | ||
| Q2 24 | $272.9M | $569.4M | ||
| Q1 24 | $299.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-12.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | -21.2% | -174.0% |
| 资本支出强度资本支出/营收 | 0.5% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-20.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BZFDRGNX
| Q4 25 | $-11.7M | $-52.3M | ||
| Q3 25 | $1.7M | $-56.0M | ||
| Q2 25 | $-10.1M | $-49.3M | ||
| Q1 25 | $1.3M | $33.6M | ||
| Q4 24 | $-4.6M | $-31.6M | ||
| Q3 24 | $9.6M | $-40.5M | ||
| Q2 24 | $-12.4M | $-45.5M | ||
| Q1 24 | $-13.3M | $-55.5M |
自由现金流BZFDRGNX
| Q4 25 | $-12.0M | $-52.8M | ||
| Q3 25 | $892.0K | $-56.5M | ||
| Q2 25 | $-10.5M | $-49.7M | ||
| Q1 25 | $956.0K | $32.6M | ||
| Q4 24 | $-4.7M | $-32.7M | ||
| Q3 24 | $9.3M | $-40.9M | ||
| Q2 24 | $-12.5M | $-46.0M | ||
| Q1 24 | $-13.4M | $-56.0M |
自由现金流率BZFDRGNX
| Q4 25 | -21.2% | -174.0% | ||
| Q3 25 | 1.9% | -189.9% | ||
| Q2 25 | -22.7% | -232.8% | ||
| Q1 25 | 2.7% | 36.6% | ||
| Q4 24 | -8.4% | -154.2% | ||
| Q3 24 | 16.7% | -168.9% | ||
| Q2 24 | -30.5% | -206.2% | ||
| Q1 24 | -36.2% | -358.5% |
资本支出强度BZFDRGNX
| Q4 25 | 0.5% | 1.7% | ||
| Q3 25 | 1.8% | 1.7% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 1.1% | 1.2% | ||
| Q4 24 | 0.3% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 0.2% | 3.6% |
现金转化率BZFDRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -0.15× | — | ||
| Q3 24 | 4.59× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BZFD
| Advertising | $25.6M | 45% |
| Commerce And Other | $16.3M | 29% |
| Content | $14.7M | 26% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
